X

Drug Profile

Research programme: chymase inhibitors - Bayer/Celera Genomics

Alternative Names: Chymase inhibitors research programme - Bayer/Celera Genomics

Latest Information Update: 10 Dec 1998

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celera Genomics Group
Developer Bayer; Celera Genomics Group
Class
Mechanism of Action Chymase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Heart failure; Respiratory tract disorders; Rheumatoid arthritis

Most Recent Events

10 Dec 1998 Discontinued-Preclinical for Heart failure in USA (Unknown route)
10 Dec 1998 Discontinued-Preclinical for Respiratory tract disorders in USA (Unknown route)
10 Dec 1998 Discontinued-Preclinical for Rheumatoid arthritis in USA (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com